Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Susan O'Brien, Jorge Cortes, Hagop M Kantarjian

Journal: Clinical lymphoma, myeloma & leukemia 2014;13(5):530-3

PMID: 23790799

Free Full Text on PubMed Central View on PubMed

Abstract

Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

Address: The University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX. Electronic address: [email protected].

DOI: 10.1016/j.clml.2013.03.017

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/23790799

Subscription / membership required

Full Text Sources:

MeSH Terms: Angiogenesis Inhibitors, Antineoplastic Agents, Phytogenic, Drug Approval, Harringtonines, Homoharringtonine, Humans, Leukemia, Myeloid, United States, United States Food and Drug Administration